The low-risk TAVR trials-A critical appraisal of the current landscape
- PMID: 40744194
- DOI: 10.1016/j.ahj.2025.07.070
The low-risk TAVR trials-A critical appraisal of the current landscape
Abstract
The low-risk TAVR vs SAVR RCTs - PARTNER-3, Evolut Low-Risk, DEDICATE, and NOTION-2 - demonstrate that TAVR is at least as effective as SAVR in terms of early mortality and disabling stroke, although outcomes varied across studies. The excellent outcomes observed in the PARTNER-3 trial reflect the highly selected patient population, while the NOTION-2 trial highlights the challenges posed by anatomical variations, such as bicuspid aortic valves (AV). These findings highlight the importance of a personalized approach guided by a multidisciplinary Heart Team, taking into account both clinical and anatomical aspects when choosing between TAVR and SAVR. Trial registration number: ClinicalTrials.gov NCT02825134.
Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest Predergast, B is member of the Anteris Technologies Advisory Board, Medtronic Trial Steering Committee and Valvosoft Data Safety Monitoring Committee. Leon, M has received grants from Edwards Lifesciences, Abbott Vascular and Medtronic, consultant fees from Foldax and Anteris Technologies, is a member of the Medtronic Data Safety Monitoring Board, has a leadership role in the Heart Valve Collaboratory and stock equity in Pi-Cardia; Søndergaard, L. is an employee at Abbott. De Baclker, O. received institutional research grants and consulting fees from Abbott, Boston Scientific, and Medtronic.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical
